Market Overview:
The global sickle cell anemia therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of sickle cell anemia, rising awareness about available treatments, and technological advancements in the field of sickle cell anemia therapeutics. Based on type, the global sickle cell anemia therapeutics market can be segmented into blood transfusion, pharmacotherapy, bone marrow transplantation, and other therapies. The blood transfusion segment is expected to account for the largest share of the global market in 2018. This segment is projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030 due to increasing use of blood transfusions as a treatment for patients with sickle cell anemia across regions.
Product Definition:
Sickle Cell Anemia Therapeutics is a type of medication that is used to treat sickle cell anemia. This medication can help to improve the overall health of someone who has this condition and can help to reduce the number of sickle cell crises that they experience.
Blood Transfusion:
Blood transfusion is the process of replacing blood lost from a patient's body. It is mainly done to replace blood volume lost due to severe bleeding or anemia. Blood transfusion in sickle cell disease (SCD) therapeutics market, helps in providing symptomatic relief and prevents complications of life-threatening proportions.
Pharmacotherapy:
Pharmacotherapy is the use of drugs to treat a disease. In sickle cell anemia therapeutics, drugs are used to reduce pain and prevent complications from occurring in people with sickle cell disease. There are various pharmacotherapies available for the treatment of this life-threatening disorder including analgesics, antibiotics, antifungal agents/antibacterial medication among others.
Application Insights:
The others segment held the largest share of the global market in 2017. This segment includes home healthcare and other non-clinical applications such as industrial, which accounted for a substantial revenue share. The growing importance of sickle cell trait and its rising prevalence are expected to boost the growth of this application segment during the forecast period.
Hospitals were estimated as the largest revenue generating centers due to their large patient base that consists mostly of adults with chronic diseases such as diabetes mellitus, cancer and cardiovascular diseases requiring hospitalization or intensive care unit (ICU) admission for treatment. In addition, hospitals account for a larger number of transfusion procedures compared to clinics or other medical facilities owing to high mortality rates associated with SCA among hospitalized patients coupled with high unmet needs regarding access to effective therapies are some factors responsible for its dominance in this sector over recent years.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of patients suffering from SCA, increasing healthcare expenditure and awareness about available treatment options are some factors attributing to its largest share. Moreover, the availability of reimbursement facilities for Sickle Cell Disease (SCD) treatments is also expected to contribute towards its large revenue share over the forecast period.
The Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to an increase in healthcare spending by governments and private organizations as well as rising patient awareness levels regarding various treatment options for chronic disorders. In addition, economic development coupled with improvement in living standards has led to an increase in immigration from underdeveloped countries such as Nigeria and Ethiopia which further increases target population size for this disease leading toward higher revenue generation capacity of pharmaceutical companies operating within this region during the forecast period.
Growth Factors:
- Increasing incidence of sickle cell anemia
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective therapies for sickle cell anemia
- Technological advancements in the field of sickle cell anemia therapeutics
- Growing number of clinical trials being conducted on new drugs and therapies for treating sickle cell anemia
Scope Of The Report
Report Attributes
Report Details
Report Title
Sickle Cell Anemia Therapeutics Market Research Report
By Type
Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant, Sickle Cell Anemia Therapeutic
By Application
Hospitals, Clinics, Others
By Companies
BioMarin, Bluebird Bio, DeuteRx, Emmaus Medical, Gamida Cell, Global Blood Therapeutics, GlycoMimetics, Modus Therapeutics, Pfizer, Sancilio Pharmaceuticals, Sangamo Biosciences, Sickle Cell Anemia Therapeutic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Sickle Cell Anemia Therapeutics Market Report Segments:
The global Sickle Cell Anemia Therapeutics market is segmented on the basis of:
Types
Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant, Sickle Cell Anemia Therapeutic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BioMarin
- Bluebird Bio
- DeuteRx
- Emmaus Medical
- Gamida Cell
- Global Blood Therapeutics
- GlycoMimetics
- Modus Therapeutics
- Pfizer
- Sancilio Pharmaceuticals
- Sangamo Biosciences
- Sickle Cell Anemia Therapeutic
Highlights of The Sickle Cell Anemia Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
- Sickle Cell Anemia Therapeutic
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sickle Cell Anemia Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sickle cell anemia therapeutics are medications that are used to treat sickle cell anemia. These medications help to improve the symptoms of sickle cell anemia, including pain, fatigue, and shortness of breath.
Some of the major companies in the sickle cell anemia therapeutics market are BioMarin, Bluebird Bio, DeuteRx, Emmaus Medical, Gamida Cell, Global Blood Therapeutics, GlycoMimetics, Modus Therapeutics, Pfizer, Sancilio Pharmaceuticals, Sangamo Biosciences, Sickle Cell Anemia Therapeutic.
The sickle cell anemia therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sickle Cell Anemia Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sickle Cell Anemia Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sickle Cell Anemia Therapeutics Market - Supply Chain
4.5. Global Sickle Cell Anemia Therapeutics Market Forecast
4.5.1. Sickle Cell Anemia Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sickle Cell Anemia Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Sickle Cell Anemia Therapeutics Market Absolute $ Opportunity
5. Global Sickle Cell Anemia Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Type
5.3.1. Blood Transfusion
5.3.2. Pharmacotherapy
5.3.3. Bone Marrow Transplant
5.3.4. Sickle Cell Anemia Therapeutic
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Sickle Cell Anemia Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Sickle Cell Anemia Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Sickle Cell Anemia Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Sickle Cell Anemia Therapeutics Demand Share Forecast, 2019-2026
9. North America Sickle Cell Anemia Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Type
9.7.1. Blood Transfusion
9.7.2. Pharmacotherapy
9.7.3. Bone Marrow Transplant
9.7.4. Sickle Cell Anemia Therapeutic
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Sickle Cell Anemia Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Sickle Cell Anemia Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Type
10.7.1. Blood Transfusion
10.7.2. Pharmacotherapy
10.7.3. Bone Marrow Transplant
10.7.4. Sickle Cell Anemia Therapeutic
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Sickle Cell Anemia Therapeutics Demand Share Forecast, 2019-2026
11. Europe Sickle Cell Anemia Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Type
11.7.1. Blood Transfusion
11.7.2. Pharmacotherapy
11.7.3. Bone Marrow Transplant
11.7.4 Sickle Cell Anemia Therapeutic
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Sickle Cell Anemia Therapeutics Demand Share, 2019-2026
12. Asia Pacific Sickle Cell Anemia Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Type
12.7.1. Blood Transfusion
12.7.2. Pharmacotherapy
12.7.3. Bone Marrow Transplant
12.7.4. Sickle Cell Anemia Therapeutic
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Sickle Cell Anemia Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Sickle Cell Anemia Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size and Volume Forecast by Type
13.7.1. Blood Transfusion
13.7.2. Pharmacotherapy
13.7.3. Bone Marrow Transplant
13.7.4. Sickle Cell Anemia Therapeutic
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Sickle Cell Anemia Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Sickle Cell Anemia Therapeutics Market: Market Share Analysis
14.2. Sickle Cell Anemia Therapeutics Distributors and Customers
14.3. Sickle Cell Anemia Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. BioMarin
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bluebird Bio
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. DeuteRx
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Emmaus Medical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Gamida Cell
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Global Blood Therapeutics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GlycoMimetics
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Modus Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pfizer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sancilio Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Sangamo Biosciences
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sickle Cell Anemia Therapeutic
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook